Elisabeth Potter Md PLLC

Medical practice

Based in TX

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $440K in lobbying spend across 16 quarterly filings, Elisabeth Potter Md PLLC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2022 to 2025.

$440K
Total Spend
4
Years Active
1
Firms Hired
9
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2022$80K
2023$120K
2024$120K
2025$120K

Issues Lobbied

Medicare/Medicaid

Lobbying Firms

Farragut Partners LLP

Lobbyists

William KriegerJody GaleSarah WalterKristen BautzJeffery MortierEdward WhitfieldJeff MackinnonDylan MooreConstantine Hingson

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid

  • •Issues related to coverage policy for Medicare reimbursement of breast reconstruction surgery
  • •Issues related to coverage policy for Medicare reimbursement of breast reconstruction surgery.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Mckesson Corporation & Affiliates U.S. Oncology and Rx Savings Solutions
$22.7M total spend
Doctors Hospital at Renaissance
$4.6M total spend
The University of Texas Md Anderson Cancer Center
$3.5M total spend
Childrens Health System of Texas
$2.8M total spend
Livanova USA, INC.
$2.7M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.